Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health (NYSE:BHC) reported strong Q2 2025 financial results with consolidated revenues of $2.53 billion, up 5% year-over-year. The company achieved GAAP Net Income of $148 million and Adjusted EBITDA of $842 million, marking its ninth consecutive quarter of growth.

Key segment performance includes Salix segment growth of 12% driven by Xifaxan®, Solta Medical segment growth of 25%, and Bausch + Lomb segment growth of 5%. The company announced plans to repay approximately $900 million in debt and entered an agreement to acquire DURECT Corporation to expand its hepatology portfolio.

Management reaffirmed its full-year 2025 guidance, projecting consolidated revenues of $10.0-10.25 billion and Adjusted EBITDA of $3.485-3.635 billion.

Bausch Health (NYSE:BHC) has announced a definitive agreement to acquire DURECT Corporation (NASDAQ:DRRX) in a deal valued at approximately $63 million upfront, with potential additional milestone payments of up to $350 million. The acquisition price represents a 217% premium to DURECT's closing price.

The key asset in this acquisition is larsucosterol, an epigenetic modulator with FDA Breakthrough Therapy Designation for treating alcoholic hepatitis (AH). The drug has shown promising results in Phase 2 trials and addresses a significant unmet medical need, as AH accounts for 164,000 hospital admissions in the U.S. annually with no FDA-approved treatments currently available.

The transaction is expected to close in Q3 2025, subject to customary conditions including majority shareholder tender. The deal complements Bausch Health's existing hepatology portfolio, particularly their Phase 3 rifaximin SSD program.

Bausch Health (NYSE:BHC) has announced significant debt reduction initiatives totaling approximately $900 million. The company will redeem $602 million of its 9.25% Senior Notes due 2026 using cash on hand, with the redemption date set for August 28, 2025.

Additionally, Bausch's subsidiary plans to repay $300 million outstanding under its Receivables Facility, with termination scheduled for October 27, 2025. These strategic moves align with the company's objective to optimize its capital structure.

Bausch Health (NYSE:BHC) has expanded its Board of Directors from ten to twelve members with the appointment of two seasoned pharmaceutical industry executives, effective July 22, 2025. Michael Goettler, former CEO of Viatris, will serve on the Talent and Compensation Committee and Science and Technology Committee. Sandra Leung, former Executive VP and General Counsel of Bristol Myers Squibb, will join the Nominating and Corporate Governance Committee.

Board Chairman John A. Paulson expressed confidence that their extensive industry experience and leadership capabilities will provide strategic guidance for the company's continued evolution and strengthen its commitment to stakeholders.

Bausch Health Canada (NYSE:BHC) announced that its acne treatment CABTREO is now available through public drug plans in Ontario and Nova Scotia, as well as two federal programs - the Non-Insured Health Benefits (NIHB) for Indigenous populations and the Correctional Service of Canada (CSC).

CABTREO is a first-of-its-kind triple-combination topical prescription treatment for acne vulgaris, approved by Health Canada for patients 12 years and older. The treatment combines three mechanisms of action: an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The once-daily gel is currently available through most private insurance plans, with plans to expand access through other public drug plans across Canada.

Bausch Health (NYSE:BHC) has appointed Steven Lee as Senior Vice President, Controller and Chief Accounting Officer, effective July 14, 2025. Lee brings over two decades of experience in financial transformation, mergers and acquisitions, and operational execution.

Prior to joining Bausch Health, Lee served as Vice President and CFO of the Industrial and Energy Division and North America Division at BrandSafway, where he also held the position of Chief Accounting Officer. His previous experience includes leadership roles at Mohawk Industries as VP, Corporate Controller, and Chief Accounting Officer.

Bausch Health Canada (NYSE:BHC) announced that its acne treatment CABTREO is now available through public drug plans in Ontario and Nova Scotia, as well as federal programs NIHB and CSC. CABTREO is a first-of-its-kind triple-combination topical treatment for acne vulgaris in patients 12 years and older.

The prescription gel combines three mechanisms of action: an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The treatment is administered once daily to affected skin areas and has already been available through most private drug insurance plans.

Bausch Health (NYSE:BHC) and its gastroenterology business, Salix Pharmaceuticals, have launched a new direct-to-consumer campaign called "I Wish I Knew" for their FDA-approved drug Xifaxan® (rifaximin). The campaign aims to educate about overt hepatic encephalopathy (OHE), a serious complication affecting cirrhosis patients.

The initiative features a 60-second spot highlighting a patient's journey with OHE and treatment with Xifaxan, alongside three new patient testimonials. The campaign emphasizes that up to 80% of cirrhosis patients may develop some form of hepatic encephalopathy, which can cause alterations in consciousness, cognition, and behavior.

The company is collaborating with patient advocacy organizations including Global Liver Institute and American Liver Foundation to raise awareness about chronic liver disease progression and OHE management.

Bausch Health (NYSE:BHC) has scheduled its second quarter 2025 financial results announcement for July 30, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. EDT to discuss the results and provide a business update.

The presentation materials will be available on the company's Investor Relations website before the call, and a replay will be accessible afterward at ir.bauschhealth.com/events-and-presentations.